Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2012 September;37(3) > Minerva Endocrinologica 2012 September;37(3):221-31

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

  ENDOCRINE AND ORGAN TRANSPLANTATION


Minerva Endocrinologica 2012 September;37(3):221-31

language: English

Osteoporosis after solid organ transplantation

Kulak C. A. M. 1, 2, Cochenski Borba V. Z. 1, 2, Kulak J. Jr. 3, Ribeiro Custódio M. 4

1 Department of Internal Medicine, Federal University of Parana, Curitiba, Brazil;
2 Endocrinology Division (SEMPR), Federal University of Parana, Curitiba, Brazil;
3 Department of Obstetrics & Gynecology, Federal University of Parana, Curitiba, Brazil;
4 Department of Internal Medicine, Nephrology Division, Federal University of Paulo, São Paulo, Brazil


PDF  


Osteoporosis and high risk of fractures have emerged as frequent and devastating complications of organ solid transplantation process. Bone loss after organ transplant is related to adverse effects of immunosuppressive drugs on bone remodeling and bone quality. Many factors contribute to the pathogenesis of osteoporosis in transplanted patients. This review address the mechanisms of bone loss that occurs both in the early and late post-transplant periods including the contribution of the immunosuppressive agents as well as the specific features to bone loss after kidney, lung, liver and cardiac transplantation. Therapy for bone loss and prevention of fragility fracture in the transplant recipient will also be discussed.

top of page

Publication History

Cite this article as

Corresponding author e-mail

kulakjc@gmail.com